US009408893B2

(12) **United States Patent**
Niemöeller et al.

(10) **Patent No.: US 9,408,893 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **PHARMACEUTICAL COMBINATION FOR USE IN GLYCEMIC CONTROL IN DIABETES TYPE 2 PATIENTS**

(75) Inventors: **Elisabeth Niemöeller**, Frankfurt am Main (DE); **Isabel Müehlen-Bartmer**, Frankfurt am Main (DE); **Louise Silvestre**, Paris (FR); **Gabor Boka**, Paris (FR); **Patrick Miossec**, Paris (FR)

(73) Assignee: **Sanofi-Aventis Deutschland GMBH**, Frankfurt am Main (DE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/595,590**

(22) Filed: **Aug. 27, 2012**

(65) **Prior Publication Data**

US 2013/0203666 A1 Aug. 8, 2013

(30) **Foreign Application Priority Data**

Aug. 29, 2011 (EP) 11179149

(51) **Int. Cl.**

A61K 38/26	(2006.01)
C07K 14/605	(2006.01)
A61P 3/10	(2006.01)
A61K 31/155	(2006.01)
A61K 31/4439	(2006.01)
A61K 31/427	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 38/26*** (2013.01); ***A61K 31/155*** (2013.01); ***A61K 31/427*** (2013.01); ***A61K 31/4439*** (2013.01)

(58) **Field of Classification Search**

CPC . A61K 38/26; A61K 31/155; A61K 31/4439; A61K 31/427; A61K 2300/00

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,758,683	A	9/1973	Jackson
3,868,358	A	2/1975	Jackson
3,984,696	A	10/1976	Collica et al.
4,153,689	A	5/1979	Hirai et al.
4,258,134	A	3/1981	Yoshida et al.
4,367,737	A	1/1983	Kozam et al.
4,608,364	A	8/1986	Grau
4,614,730	A	9/1986	Hansen et al.
4,644,057	A	2/1987	Bicker et al.
4,689,042	A	8/1987	Sarnoff et al.
4,701,440	A	10/1987	Grau
4,731,405	A	3/1988	Kirsch et al.
4,783,441	A	11/1988	Thurow
4,839,341	A	6/1989	Massey et al.
4,863,902	A	9/1989	Amagase et al.
4,885,164	A	12/1989	Thurow
4,923,162	A	5/1990	Fleming et al.
4,959,351	A	9/1990	Grau
4,960,702	A	10/1990	Rice et al.
4,994,439	A	2/1991	Longenecker et al.
5,006,718	A	4/1991	Lenhart
5,008,241	A	4/1991	Markussen et al.
5,034,415	A	7/1991	Rubin
5,070,186	A	12/1991	Joergensen
5,101,013	A	3/1992	Dorschug et al.
5,177,058	A	1/1993	Dorschug
5,187,177	A	2/1993	Garzaran
5,227,293	A	7/1993	Stengelin et al.
5,253,785	A	10/1993	Haber et al.
5,272,135	A	12/1993	Takruri
5,358,708	A	10/1994	Patel
5,358,857	A	10/1994	Stengelin et al.
5,370,629	A	12/1994	Michel et al.
5,397,771	A	3/1995	Bechgaard et al.
5,407,609	A	4/1995	Tice et al.
5,424,286	A	6/1995	Eng
5,428,006	A	6/1995	Bechgaard et al.
5,473,049	A	12/1995	Obermeier et al.
5,474,978	A	12/1995	Bakaysa et al.
5,478,323	A	12/1995	Westwood et al.
5,496,924	A	3/1996	Habermann et al.
5,506,203	A	4/1996	Backstrom et al.
5,509,905	A	4/1996	Michel et al.
5,514,646	A	5/1996	Chance et al.
5,524,286	A	6/1996	Chiesa et al.
5,535,488	A	7/1996	Hoffman
5,545,618	A	8/1996	Buckley et al.
5,547,929	A	8/1996	Anderson, Jr. et al.
5,559,094	A	9/1996	Brems et al.
5,595,756	A	1/1997	Bally et al.
5,597,796	A	1/1997	Brange
5,614,219	A	3/1997	Wunderlich et al.

(Continued)

FOREIGN PATENT DOCUMENTS

AU	1986-62066	3/1987
AU	1987-75916	1/1988

(Continued)

OTHER PUBLICATIONS

Christensen et al, Lixisenatide, a noveL GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus, IDrugs, 2009, 12, pp. 503-513.*

NCT00763815, from http://clinicaltrials.gov/ct2/show/NCT00763815?term=NCT00763815&rank=1, pp. 1-3, accessed Sep. 12, 2013.*

Yki-Järvinen et al, Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study, Diabetologia, 2006, 49, pp. 442-451.*

(Continued)

Primary Examiner — Julie Ha

Assistant Examiner — Li Ni Komatsu

(74) *Attorney, Agent, or Firm* — McDonnell Boehnen Hulbert & Berghoff LLP

(57) **ABSTRACT**

The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.

2 Claims, 4 Drawing Sheets